Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open-Label, Single-arm, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of SY-5007 in Patients With RET-altered Advanced Solid Tumor.

NCT05278364 is registered in ClinicalTrials.gov with Shouyao Holdings (Beijing) Co. LTD as lead sponsor.

NCT NCT05278364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05278364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open-Label, Single-arm, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antineoplastic Activity of SY-5007 in Patients With RET-altered Advanced Solid Tumor.
Lead sponsor
Shouyao Holdings (Beijing) Co. LTD
Phase
Phase 1/2
Overall status
Unknown status
Start date
April 23, 2021
Completion date
February 10, 2025
Enrollment
184 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

medullary thyroid cancer, non-small cell lung cancer, solid tumor